As a service to the global R&D community, Science|Business has compiled this database of funding opportunities. Users are encouraged to let us know of funding calls that could be incorporated into the database. Please email all suggestions to [email protected]. The database will be updated daily. For rapid news about COVID-19, see our live blog.
This call aims to strengthen the evidence base to better prevent and control coronavirus (COVID-19) epidemics and to increase research and response capacity.
Amount
Up to £2M
Agency or Funder
Wellcome Trust & UK Department for International Development (DFID)
Eligibility (if available)
PhD plus significant postdoctoral experience in an academic research organisation, a not-for-profit or government body, a private sector organisation
Any aspect of coronavirus research. Applicants may request up to 300,000 francs for projects lasting up to 24 months. Bigger grants are conceivable, provided the applicant has good reasons for requesting a higher amount.
A call for R&D projects that can quickly contribute to improving the response of health systems to the impact of COVID-19, contributing to better patient management and the implementation of public health measures.
Cardiovascular-focused applications that will contribute to understanding the cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social beha
Part of the third phase of the PIPE programme, aimed at Innovative Research for SMEs. Its objective is to support research for SMEs which have conducted innovative research in the past.
A rapid call to Austria businesses for COVID-19 projects lasting no longer than 12 months. To accelerate decision making, this call has a deadline of 8 April; a second call will have a deadline of 11 May.
The call will specifically give support to clinical and translational proposals that include clearly targeted technologies or projects to prevent, treat, monitor, or diagnose the COVID-19 disease.
Amount
€300,000
Agency or Funder
'La Caixa'' Foundation
Eligibility (if available)
Non-profit legal entities based in Spain or Portugal.
Funding for public and private research into COVID-19 in the areas of epidemiological studies, diagnostics, therapeutics, behavioural science, mental health, and the development of medical and ICT devices.
Amount
PYG 300M to PYG 1B, up to 90% of project costs
Agency or Funder
Consejo Nacional de Ciencia y Tecnología, Paraguay
Eligibility (if available)
Universities, NGOs, private and public sector organisations
A call for novel therapies, broad-spectrum antivirals, next-generation vaccines that may target new corona strains, multiple corona viruses or more than one type of virus, and strategies for first responders and emergency medical personnel.
Amount
$150.000 (U.S.) guaranteed, with the potential to receive up to $1 million
Agency or Funder
Harrington Discovery Institute
Eligibility (if available)
Project lead must have an MD, PhD or equivalent and based in the U.S., UK or Canada.
Proposals should address COVID-19 infection in malignant and benign haematologic disorders or haematological and immunological manifestations in COVID-19 infection.
A rapid call to Austria businesses for COVID-19 projects lasting no longer than 12 months. The second part of the rapid call (the first part has a deadline of 8 April).
A £10 million fund to support research to accelerate the development and testing of therapeutics that can be rapidly deployed to treat the symptoms of COVID-19.
Amount
£10M
Agency or Funder
LifeArc
Eligibility (if available)
Academics, NHS employees or companies that have therapeutics that could be repurposed or repositioned for use in COVID-19 patients
Proposals sought for a clinical trial that accelerates the implementation of treatments for severe acute respiratory distress in patients infected with COVID-19 in order to support the response to the COVID-19 outbreak in Australia.
Amount
$5M AUD
Agency or Funder
Australian National Health and Medical Research Council (NHMRC)
Eligibility (if available)
Applications will only be accepted from NHMRC approved Administering Institutions
Funding for clinical trials to evaluate new drugs, devices, clinical guidance, approaches and technologies aimed at stopping the spread of COVID-19. Projects may range from proof-of-concept to large-scale trials.
Amount
$30M (U.S.)
Agency or Funder
US Army Medical Research Acquisition Activity
Eligibility (if available)
Principal investigator must be at level of Assistant Professor or equivalent.
This funding opportunity will be a complementary financial support for researchers financed by grants from Tematico program, Centres of Research, Innovation and Diffusion (CEPID), Engineering Research Centres (CPEs) and Young researchers
Amount
R$10M
Agency or Funder
São Paulo Research Foundation (FAPESP)
Eligibility (if available)
Researchers financed in the areas of Tematico, Young Researcher, CEPID and CPE
Applications must address clinical (hospital or outpatient) or community-related aspects of COVID-19. Translational projects will be preferred. Basic research at the cellular level, or into animals, will not be considered.
Amount
$25,000 USD
Agency or Funder
CHEST Foundation
Eligibility (if available)
Health professionals, clinical researchers and non-profts that are members of CHEST
Projects lasting up to 9 months should collect data on the clinical course and outcome of COVID-19 in vulnerable populations, investigate long-term consequences of COVID-19 in patients, or test the safety and effectiveness of remdesivir in treatin